Aim of present study was to develop a simple, precise and accurate LC-UV method for the cyclosporine A (CyA) estimation in microemulsion formulation and in vitro release samples in phosphate buffer pH 6.8. CyA was separated on Hibar ® 250-4,6 LiChrospher ® 100 RP-18e (5µm) column at 70 o C with 1mL/min flow rate using acetonitrile:methanol:water (pH=3.5 with 0.5% orthophosphoric acid) :: 65:25:10 as mobile phase and methanol as diluent. The method successfully resolved the co eluting peaks obtained during in vitro release study samples with reproducible retention time of CyA. The drug content was also analyzed during thermodynamic stability testing of formulation and was found to be 98.13 ± 2.29%. The protein binding affinity of CyA was estimated to be 98.95 ± 0.1%. A validated method was used for quantification of free drug and bound drug using albumin as protein substrate. Protein binding affinity of drug was assessed using standard equilibrium dialysis method and protein binding characteristic was studied using Scatchard plot. The newly developed method is suitable for accurate estimating of CyA in self emulsifying microemulsions and hence proving its clinical potential.
Introduction
Cyclosporine (CyA) is a potent immunosuppressant macrolide, a lipophilic cyclic polypeptide, composed of 11 amino acids with molecular weight of 1202.6Da. It is produced as a metabolite by the fungus species Beauveria nivea. It is the first-class therapeutic medication clinically used to prevent allograft rejection in organ transplantations and to treat autoimmune disorders. The therapeutic window of CyA is narrow and associated with serious side effects if dose exceeds a therapeutic range. Also if it does not reach a therapeutic range it may leads to graft rejection.
Immunosuppressive therapy is necessary in organ transplant surgery and is associated with nephrotoxicity, cardiotoxicity and neurotoxicity. Therefore monitoring accurate CyA levels in organ transplant patients is important. Moreover in various dosage forms where a drug is mixed with other excipients, it is necessary to determine the CyA concentrations precisely. Blood sample determination of patients for CyA is very critical because of individual variations in absorption, distribution, metabolism and elimination processes (Jaklitsch, Monger et al. 1998, Mika and Stepnowski 2016) . CyA has very low water solubility (6.6μg/mL) at 37°C, as a consequence it suffers from low oral bioavailability as dissolution is a limiting factor for absorption (Xu, Gupta et al. 2013) . CyA is marketed in various dosage forms in order to overcome its solubility and dissolution associated absorption e.g. oral solutions, liquid filled soft gelatin capsules (Neoral ® , Sandimmune ® ), parenterals (Sandimmune ® ) and emulsion for ophthalmic administration (Restasis ® ). Few and sporadic literature is available with reference to the analysis of CyA. The problem associated with HPLC analysis of CyA is the broadening of peak which is due to the multiconformational changes in the peptide structure, as a consequence it is very difficult to resolve drug peak from additional peaks that occurs due to excipients or degraded products in various dosage forms. Therefore, for satisfactory resolution and sensitivity, these factors make the analysis of CyA very cumbersome and erratic. Various literature reports have suggested that temperature has significant influence on chromatographic analysis of CyA i.e. above 60°C CyA undergoes conformational changes and converted almost into one form which leads to decrease in characteristic broadening of peak (T. . In addition to this, low pH (pH ≤ 3.0) also shows better resolution and increased sensitivity (Zaghloul, Hussain et al. 2003) . Despite of great advancement in analysis of immunosuppressants including immunological based methods, there is still a great need for rapid, selective, sensitive and easily accessible method to analyze CyA, a potent drug known for its narrow therapeutic window. The purpose of this study was to develop and validate a simple, cost effective and clinically useful LC method to analyze the release samples of CyA in the formulation. Here CyA is formulated into self-microemulsifying drug delivery system (SMEDDS); which gives an edge over the other formulations, as CyA is a poor water soluble drug. The developed analytical method provides precise resolution of the co-eluting peaks which is one of the big hindrances in the analysis of CyA. The method has also an advantage of relatively short run time as drug is precisely estimated at retention time 6.0min with good resolution of interfering peaks. Long HPLC run time are not suitable for pediatric studies, unstable compounds (Chu, Kiang et al. 1999) . Also solvent wastage, time consuming and complexity of methods are not appreciated commercially. Further, the developed method has been used to analyze the drug content in thermodynamic stability testing of SMEDDS. The study has been extended to assess the dissolution profile and drug protein binding.
Materials and Methods

Instrumentation and chromatographic conditions
A Shimadzu UFLC instrument equipped with quaternary gradient pump (Prominence LC-20AD), autosampler, online degasser (DGU 20 A5), photodiode detector (SPD-M 20A), column oven (CTO10ASvp) and system controller (CBM 20Alite) was used for the present study. Data collection and interpretation were performed by Lab Solution Lite PDA software. Partitioning was achieved on Hibar ® 250-4,6 LiChrospher ® 100 RP-18e (5µm) HPLC column. Mobile phase comprised acetonitrile: methanol: water (pH 3.5 using orthophosphoric acid) in a ratio 65:25:10 with flow rate of 1mL/min. The temperature of column oven was maintained at 70°C. The injection volume was 10µl and data interpretation was done at 205nm. Due to insufficient chromophoric, groups the UV detection of CyA occurs at short wavelength (Pecchio, Salman et al. 2014) .
Preparation of stock solution, calibration samples and quality control samples
Accurately weighed 10mg CyA was dissolved in methanol and a stock solution of 100µg/mL was prepared. Further seven levels of calibration standards in the range 4 to 80µg/mL were prepared by diluting the stock solutions with methanol. All drug samples were protected from light by using amber coloured glass apparatus. Quality control standards were prepared by diluting a stock solution of 100µg/mL CyA with methanol to obtain concentrations of 8, 20 and 40µg/mL.
Linearity and range
Range is defined as the interval between the minimum and maximum concentration which is analyzed by the given analytical method on given chromatographic conditions within permissible limits of precision and accuracy. Seven dilutions (4 to 80µg/mL) of CyA in methanol were prepared and analyzed in triplicate.
Precision
Intraday and interday precision were determined by analyzing three concentrations i.e. 8, 20 and 40µg/mL. Three replicates of each concentration were analyzed on 1, 2 and 3 day for interday precision. Same set of concentrations were also analyzed in triplicate at different time within a day for intraday precision. Each set of these concentrations were prepared from three different stock solutions of strength 100µg/mL. The instrumental precision was checked by repeated injections (n=6) of 40µg/mL. The peak area was determined and the precision was reported as RSD in table 1.
Limit of detection (LOD) and Limit of quantification (LOQ)
Limit of detection is the smallest concentration, which the analytical method, on a given instrument and chromatographic conditions is able to differentiate the compound from the background noise. The limit of quantification is the smallest concentration which is quantifiable with defined precision and accuracy. Various minimum concentrations were injected and analyzed for LOQ. According to ICH guidelines LOD and LOQ can be determined on the basis of mathematical relation that depends on slope of the curve (JJM 2006) and standard deviation (σ) of y-intercept of regression lines. Mathematically LOD and LOQ were calculated using following equations (Zaghloul, Burckart et al. 1986 ):
= 10 (2) 2.6. Accuracy The preconcentrate was mixed with CyA solution and diluted with methanol to yield three final concentrations (8, 20 and 40µg/mL). To establish the accuracy in terms of percentage recovery the concentrations were analyzed in preconcentrate and were compared with respective nominal values from the calibration curve. Mathematically the percentage recovery was calculated by following equation:
The result of recovery study is presented in table 2.
Preparation of formulation and drug incorporation
SMEDDS were formulated by using maize oil, oleic acid as oil phase and Tween 20 as surfactant. The concluding composition of oil phase (maize oil and oleic acid in the ratio of 1:1), surfactant (Tween 20) and water was selected from a pseudo ternary phase diagram. CyA was dissolved under stirring into the preconcentrate containing oil mixture (maize oil and oleic acid in the ratio 1:1) 50% and surfactant 40%.
In vitro release studies
Dialysis membrane (Himedia) with molecular weight cut off 14000Da was first activated by soaking in distilled water for about 12h in order to remove the preservative agent from the membrane. After 12h, the membrane was thoroughly rinsed and soaked in fresh distilled water for about 15min. 2mL of microemulsion formulation, loaded in dialysis bag (looped from both sides) was subjected to release CyA in USP type II paddle type apparatus at 50 RPM. Dissolution was carried out at 37°C with phosphate buffer pH 6.8 with 5% ethanol to maintain sink condition as dissolution media. 5mL of sample was collected at different intervals of time (0.5, 1, 2, 3, 4 and 5h) and at the same time media was replenished with the same volume of fresh release media (Sharma, Lohan et al. 2014) .
Preparation of in vitro release samples
For sample preparation, 5mL of withdrawn samples containing microemulsion were diluted with methanol and filtered after 5min through 0.22μm nylon filters. 10μL volumes of reconstituted samples were injected through autosampler into the C-18 column for analysis.
In vitro protein binding studies
Standard equilibrium dialysis was performed using dialysis membrane with a molecular weight cut off of 10,000Da (Barre, Chamouard et al. 1985 , Lin, Musiano et al. 2005 . 5mL bovine serum albumin fraction V (BSA) (pH 6.0 to 7.0) solution of strength 500µM in phosphate buffer pH 7.4±0.5 was loaded in dialysis membrane. Loaded bags with protein solution were dipped in 50mL of varying concentrations of CyA solutions (10, 13, 15, 17, 20, 23 and 25µM) . All the concentrations were prepared in phosphate buffer pH 7.4±0.5. The dialysis process was allowed to equilibrate for 4h, at 50 rpm, in a temperature controlled water bath shaker at 37±2°C. After equilibrium was achieved the samples were withdrawn from flasks and analyzed by validated UHPLC-UV method.
Results
Validation for chromatographic method was carried out according to ICH guidelines. Method was validated for linearity, range, precision (interday and intraday), accuracy, limit of detection and limit of quantification. The acceptance criteria were less than 2% relative standard deviation for peak area. Fig. 1 illustrates the retention time of drug at 6.0min when mixed with methanol with a 3D image of chromatogram (between time, wavelength and intensity). The graph is plotted between mean ± S.D. of peak area and concentration (µg/mL) as depicted in fig. 2 . The expression was subjected to linear regression, giving a linear expression for standard calibration curve as y = 23467x with r 2 =0.999, where x represents the concentration of CyA in µg/mL. The interday, intraday and instrumental precision results are expressed in terms of relative standard deviation (RSD) ranged from 0.55% to 1.96% (Table 1) . Experimentally LOD and LOQ for cyclosporine were found 150ng/mL and 500ng/mL, respectively. A comparison between experimentally observed and mathematically calculated LOD and LOQ is presented in table 2. The percentage recovery of CyA in microemulsion at three different levels (8, 20 and 40µg/mL) was found in the range of 97.95 to 98.51% (Table 2) . 
In vitro release study
The release study revealed that preconcentrate, composed of oil (maize and oleic acid) and Tween 20 as surfactant, released almost above 85% drug in about 5h. All calculations of release were done using general formula (equation 4) for calculating corrected concentrations. Fitness of data in different kinetic models was assessed by determining correlation coefficient and the selected formulation was found to follow first order release kinetic model with r 2 = 0.864 as shown in fig. 3 .
where; Cc= Corrected concentration, Cu= Uncorrected concentration, Vs= Sample volume, Vt= Total volume, ∑
−1 =1
= Cummulative concentration at n-1.
Fig. 1. 2D and 3D representation of fingerprint chromatogram of CyA
Thermodynamic stability assay of drug
Thermodynamic stability was assessed for microemulsion over six heating-cooling cycles, where drug content was also estimated for any degradation. 20mg/mL CyA loaded microemulsion was subjected to six consecutive heating-cooling cycles by storing the microemulsion at 4 o C and then at room temperature for 48h respectively. At the end of sixth cycle, 100µL of sample was diluted with methanol and assayed using above mentioned chromatographic conditions. The drug content was analyzed in triplicate and the mean drug content was found to be 98.13 ± 2.29%. The validated method showed a good resolution with a stable baseline as shown in fig. 4 . No additional peak was observed other than CyA in the samples of thermodynamic stability assay of preconcentrate. 
Discussion
Effect of temperature on peak resolution
Temperature has a significant influence in the reverse phase liquid chromatographic UV analysis (LC-UV) of CyA (Meretoja, Churilov et al. 2014) . A study has shown that temperature leads to structural alterations in the peptide structure of CyA . But the types of structural changes have been undetected in polypeptide structure of CyA. Various reports suggest that high temperature leads to the conformational changes of CyA (Zaghloul, Burckart et al. 1986 , Xu, Gupta et al. 2013 , Szerkus, Wolska et al. 2014 . Therefore, high temperature is a critical factor for the LC-UV analysis of CyA. For this reason 70°C column temperature was found to be most favorable to avoid broadening of the peak and to get high resolution. Fig. 5 shows the changes in area under curve of CyA peak at 30, 40, 50, 60 and 70°C in the form of overlay. Increase in temperature results in sharpness of peak as well as decrease the area under curve and provide better resolution. 
Peak resolution in in vitro dissolution samples
The method described above was subjected to analyze the dissolution samples. The overlay shown in fig. 6 depicts the specificity of drug peak and additional co-eluting peaks with good resolution. These co-eluting peaks during UHPLC-UV analysis of CyA are associated with excipients of preconcentrate as seen in chromatograms of blank injections. Blank injection comprises of blank formulation in a mixture of phosphate buffer and methanol. As such it is very cumbersome to separate these interfering co-eluting peaks with the drug peak. The above developed and validated method has successfully achieved resolution and separates these peaks from the drug. Additionally, it was observed that potassium dihydrogen phosphate salt present in dissolution media (pH 6.8) gets precipitated when mixed with methanol for dilution. Therefore to avoid column choking, a sufficient dilution with methanol was done which causes the precipitation of salts and finally the sample was filtered through 0.22µm nylon filters before analysis. 
In vitro protein binding
Protein binding was assessed after equilibrium was achieved between bound ligand (CyA-BSA) and free ligand (CyA). Equilibrium dialysis method was used for determination of binding parameters, as it offers the advantage of precise and reproducible results because in this method bound ligand (CyA-BSA) and free ligand (CyA) are not separated and, hence, equilibrium remains unaffected (Barre, 1985) . We found that low concentrations of drug are important to determine protein binding in the experiment. Table 3 represents a maximum percentage protein binding at low concentrations while it decreases on increasing the drug concentration when calculated from the mathematical formula represented in equation no. 5. This is because on each set of equilibrium, albumin concentration is constant while the total drug concentration subjected for binding is varied. This means at high concentrations the binding sites under investigation get saturated and free drug concentration increases. Moreover the value for free drug concentration is proportional to total drug concentration i.e. with increase in total drug concentration the free drug concentration increases.
where, [Td] = Total drug concentration and Df = Free drug concentration.
We studied the representation of data using Scatchard plot (Fig. 7) which describes more than one set of protein binding sites as we get a curved line rather than a straight line. Also this represents a non linear relationship which explains non specific binding of CyA to albumin (Chamness, 1975 , Rosenthal, 1967 , Weder, 1974 .
Fig. 7. Scatchard plot
The determination of unbound and bound drug-protein fractions of cyclosporine is critical in patients suffering from hyperlipoproteinemia which is most commonly found in renal transplant patients (JJM, 2006) . This condition leads to irregular concentrations of CyA in blood, thus, monitoring of total CyA levels in this condition needs to be analyzed accurately. Moreover in certain disease state and/or drug induced changes in albumin affinity results in misleading CyA concentrations thus, a sensitive chromatographic method is always needed to determine CyA levels accurately.
Conclusion and Perspectives
A new sensitive, precise, accurate, linear across the range and specific UHPLC-UV method has been developed for the estimation of CyA. The method has been successfully applied to the dissolution studies, estimation of CyA content during thermodynamic stability of preconcentrate and determination of protein binding. The method is convenient and controllable because of well defined easy chromatographic conditions and effortless pretreatment of formulation and dissolution samples. In addition to this, the dissolution studies of CyA loaded preconcentrate was found to follow first order release kinetics and may be used to study the release mechanism of drug through microemulsion. Method also has clinical potential as it is used for in vitro assessment of CyA in BSA.
